Preprints.org

Oral GLP-1 Super-Responders are Characterized by Greater Pretreatment Weight Gain, Faster Early Dose Escalation, and Larger On-Treatment Blood Pressure Reductions

At a glance

Pretreatment weight trajectory and early dosing were associated with response.

The research question

What distinguishes early oral Wegovy super-responders?

Overview

Retrospective EHR analysis examined 9,287 GLP-1-naive patients prescribed oral Wegovy.

Study design & methods

Among 8,381 patients with baseline weight, 3,011 had follow-up weights at 30–180 days. Groups reflected best weight change; super-response meant >10% loss.

Principal findings

Super-responders lost 11.4% by day 90. Systolic pressure fell 10.2 mmHg versus 3.3 mmHg in non-responders. They had greater prior five-year weight gain and faster early dose escalation.

Limitations & interpretation

Preprint; not peer reviewed. Outcome-defined groups, selective follow-up, and short observation limit inference. Associations do not establish causality or justify faster titration; prospective validation is needed.

Publication type and venue follow the original nference listing. Read the original paper for full methods, analyses, and interpretation. View source listing.

Keep exploring.

All publications
CardiometabolismPreprint - Submitted for Peer-Review

Excessive Weight Loss with Zepbound Is Associated with Higher Rates of Adverse Events, Electrolyte Imbalances, and Hospitalization than Moderate Weight Loss

While residual confounding and documentation differences may contribute to some real-world associations, the significantly greater burden of adverse events, hospitalization rates, laboratory test anomalies, and vital-sign abnormalities among Zepbound patients with excessive weight loss warrants further investigation.

Preprints.org
October 21, 2026
CardiometabolismConference

Menopause Hormone Therapy and Weight Loss Response to GLP-1–Based Therapies in Midlife Women: A Retrospective Cohort Study

In this large real-world cohort of midlife women treated for overweight or obesity, concomitant HT was associated with significantly greater and sustained weight loss with SEM. A similar directional effect with TZP was observed at early timepoints but did not reach statistical significance. Larger prospective studies are warranted to confirm these observations and to inform individualized treatment strategies in midlife women.

The Menopause Society — 2026 Annual Meeting
October 20, 2026
Your next question could change everything.

What will you
discover next?

Let’s find out
Ideas are connected. Your next discovery starts here.